DDInter128 DDInter1676
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Astemizole {u} (Compound) resembles {v} (Compound) Fentanyl
Astemizole {u} (Compound) resembles {v} (Compound) Flunarizine
Astemizole {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Astemizole {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Astemizole {u} (Compound) upregulates {v} (Gene) LIPA
Astemizole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Astemizole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Astemizole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Astemizole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Astemizole {u} may lead to a major life threatening interaction when taken with {v} Methadone
Astemizole (Compound) resembles Fentanyl (Compound)
Astemizole (Compound) resembles Flunarizine (Compound)
Astemizole may lead to a major life threatening interaction when taken with Pimozide
Astemizole (Compound) binds CYP3A7-CYP3A51P (Gene)
Astemizole (Compound) upregulates LIPA (Gene)
Astemizole (Compound) downregulates RPS4Y1 (Gene)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Astemizole may lead to a major life threatening interaction when taken with Methadone